EGFR-Mutated Lung Cancer Perspectives

In these videos, Edward B. Garon, MD, MS, associate clinical professor of medicine and hematology-oncology at the University of California Los Angeles David Geffen School of Medicine, discusses:

• Treatment options available to patients with EGFR-mutated lung cancer, such as erlotinib (Tarceva; Genentech, Astellas), afatinib (Gilotrif, Boehringer Ingelheim) and dacomitinib (Vizimpro, Pfizer), along with combined treatment approaches, including erlotinib plus ramucirumab (Cyramza, Eli Lilly);
• The challenge of treating patients with EGFR-mutated metastatic NSCLC who were previously treated with an EGFR-inhibitor and chemotherapy, as “there’s not a lot of data in support of any particular agent,” after these options are used;
• How specific subgroups of EGFR-mutated lung cancers respond to therapies and approved treatment options for these subgroups, including amivantamab (Rybrevant, Janssen) in patients with exon 20 insertions;
• Treatments in the pipeline that target patients with resistance, “the farthest along” of which are approaches targeting MET amplification, including tyrosine kinase inhibitors and antibody-drug conjugates; and
• Current research on EGFR-mutated lung cancers, including studies examining “whether or not you can combine chemotherapy with osimertinib (Tagrisso, AstraZeneca),” the combination of anti-angiogenic therapies with osmeritinib and examining MET amplification.